The Experts below are selected from a list of 108177 Experts worldwide ranked by ideXlab platform
Dick Menzies - One of the best experts on this subject based on the ideXlab platform.
-
New short regimens for latent Tuberculosis Treatment: safety first!
The European respiratory journal, 2018Co-Authors: Dick Menzies, Anete TrajmanAbstract:Safety must be the first consideration in evaluating any new regimen for latent Tuberculosis Treatment. Caution is needed when using isoniazid plus rifapentine, once or twice weekly, in individuals aged over 50 years, even for a short period.http://ow.ly/T0fT30mOs7m
-
Initial drug resistance and Tuberculosis Treatment outcomes: systematic review and meta-analysis.
Annals of internal medicine, 2008Co-Authors: Woojin Lew, Madhukar Pai, Olivia Oxlade, Daniel Martin, Dick MenziesAbstract:Optimizing Tuberculosis Treatment outcomes is increasingly difficult as drug-resistant Tuberculosis becomes more common. Lew and colleagues reviewed 22 trials and 7 cohort studies that involved 14 ...
Berihun M. Zeleke - One of the best experts on this subject based on the ideXlab platform.
-
Non-Adherence to Anti-Tuberculosis Treatment and Determinant Factors among Patients with Tuberculosis in Northwest Ethiopia
PloS one, 2013Co-Authors: Akilew Awoke Adane, Kefyalew Addis Alene, Digsu N. Koye, Berihun M. ZelekeAbstract:Background Non-adherence to anti Tuberculosis Treatment is one of the crucial challenges in improving Tuberculosis cure-rates and reducing further healthcare costs. The poor adherence to anti-Tuberculosis Treatment among patients with Tuberculosis is a major problem in Ethiopia. Hence, this study assessed level of non-adherence to anti-Tuberculosis therapy and associated factors among patients with Tuberculosis in northwest Ethiopia. Methods An institution based cross-sectional survey was conducted among Tuberculosis patients who were following anti-Tuberculosis Treatment in North Gondar zone from February 20 – March 30, 2013. Data were collected by trained data collectors using a structured and pre-tested questionnaire. Data were entered to EPI INFO version 3.5.3 and analyzed using statistical package for social sciences (SPSS) version 20. Multiple logistic regressions were fitted to identify associations and to control potential confounding variables. Odds ratio (OR) with 95% confidence interval was calculated and p-values
-
non adherence to anti Tuberculosis Treatment and determinant factors among patients with Tuberculosis in northwest ethiopia
PLOS ONE, 2013Co-Authors: Akilew Awoke Adane, Kefyalew Addis Alene, Digsu N. Koye, Berihun M. ZelekeAbstract:Background Non-adherence to anti Tuberculosis Treatment is one of the crucial challenges in improving Tuberculosis cure-rates and reducing further healthcare costs. The poor adherence to anti-Tuberculosis Treatment among patients with Tuberculosis is a major problem in Ethiopia. Hence, this study assessed level of non-adherence to anti-Tuberculosis therapy and associated factors among patients with Tuberculosis in northwest Ethiopia. Methods An institution based cross-sectional survey was conducted among Tuberculosis patients who were following anti-Tuberculosis Treatment in North Gondar zone from February 20 – March 30, 2013. Data were collected by trained data collectors using a structured and pre-tested questionnaire. Data were entered to EPI INFO version 3.5.3 and analyzed using statistical package for social sciences (SPSS) version 20. Multiple logistic regressions were fitted to identify associations and to control potential confounding variables. Odds ratio (OR) with 95% confidence interval was calculated and p-values<0.05 were considered statistically significant. Results A total of 280 Tuberculosis patients were interviewed; 55.7% were males and nearly three quarters (72.5%) were urban dwellers. The overall non-adherence for the last one month and the last four days before the survey were 10% and 13.6% respectively. Non-adherence was high if the patients had forgetfulness (AOR 7.04, 95% CI 1.40–35.13), is on the continuation phase of chemotherapy (AOR: 6.95, 95% CI 1.81–26.73), had symptoms of Tuberculosis during the interview (AOR: 4.29, 95% CI 1.53–12.03), and had co-infection with HIV (AOR: 4.06, 95% CI 1.70–9.70). Conclusions Non-adherence to anti-Tuberculosis Treatment was high. Forgetfulness, being in the continuation phases of chemotherapy, having symptoms of Tuberculosis during the interview, and co-infected with HIV were significantly associated with non-adherence to anti-Tuberculosis therapy. Special attention on adherence counseling should be given to symptomatic patients, TB/HIV co-infected patients, and those in the continuation phase of the Tuberculosis therapy.
Gleide Santos De Araujo - One of the best experts on this subject based on the ideXlab platform.
-
effect of the bolsa familia programme on the outcome of Tuberculosis Treatment a prospective cohort study
The Lancet Global Health, 2019Co-Authors: Janaina Gomes Nascimento Oliosi, Barbara Reissantos, Rodrigo Leite Locatelli, Carolina Maia Martins Sales, Walter Gomes Da Silva Filho, Kerollen Cristina Da Silva Da Silva, Mauro Niskier Sanchez, Kaio Vinicius Freitas De Andrade, Gleide Santos De AraujoAbstract:Summary Background Social protection interventions might improve Tuberculosis outcomes and could help to control the epidemic in Brazil. The aim of this study was to evaluate the independent effect of the Bolsa Familia Programme (BFP) on Tuberculosis Treatment outcomes in Brazil. Methods We prospectively recruited and followed up individuals (aged ≥18 years) who initiated Tuberculosis Treatment at 42 health-care centres across seven cities in Brazil, between March 1, 2014, and April 30, 2017. Patients were interviewed at health-care centres and information about individual characteristics, socioeconomic status, living conditions, lifestyle, and comorbidities was recorded. Patients were separated into two groups according to BFP beneficiary status: BFP (exposed) or non-BFP (not exposed). Treatment outcome (cure, dropout, death, or development of drug-resistant Tuberculosis or Treatment failure) was recorded after 6 months of therapy. Pearson's χ2 test and ANOVA were used to compare Tuberculosis Treatment outcomes between the two groups, and we estimated the propensity score of being a beneficiary of the BFP using a logit model. We used multinomial regression models to evaluate the effect of the BFP on Tuberculosis Treatment outcomes. Findings 1239 individuals were included in the study, of whom 196 (16%) were beneficiaries of the BFP and 1043 (84%) were not. After 6 months of Treatment, 912 (87%) of 1043 patients in the non-BFP group and 173 (88%) of 196 patients in the BFP group were cured of Tuberculosis, 103 (10%) patients in the non-BFP group and 17 (9%) patients in the BFP group had dropped out, and 25 (3%) patients in the non-BFP group and six (3%) patients in the BFP group had died. Three ( Interpretation BFP alone had a direct effect on Tuberculosis Treatment outcome and could greatly contribute to the goals of the WHO End TB Strategy. Funding Brazilian National Council for Scientific and Technological Development (CNPq) and Brazilian Ministry of Health Department of Science and Technology (DECIT).
-
Effect of the Bolsa Familia Programme on the outcome of Tuberculosis Treatment: a prospective cohort study.
The Lancet. Global health, 2018Co-Authors: Janaina Gomes Nascimento Oliosi, Rodrigo Leite Locatelli, Carolina Maia Martins Sales, Walter Gomes Da Silva Filho, Kerollen Cristina Da Silva Da Silva, Mauro Niskier Sanchez, Kaio Vinicius Freitas De Andrade, Gleide Santos De Araujo, Barbara Reis-santos, Priya B. SheteAbstract:Summary Background Social protection interventions might improve Tuberculosis outcomes and could help to control the epidemic in Brazil. The aim of this study was to evaluate the independent effect of the Bolsa Familia Programme (BFP) on Tuberculosis Treatment outcomes in Brazil. Methods We prospectively recruited and followed up individuals (aged ≥18 years) who initiated Tuberculosis Treatment at 42 health-care centres across seven cities in Brazil, between March 1, 2014, and April 30, 2017. Patients were interviewed at health-care centres and information about individual characteristics, socioeconomic status, living conditions, lifestyle, and comorbidities was recorded. Patients were separated into two groups according to BFP beneficiary status: BFP (exposed) or non-BFP (not exposed). Treatment outcome (cure, dropout, death, or development of drug-resistant Tuberculosis or Treatment failure) was recorded after 6 months of therapy. Pearson's χ2 test and ANOVA were used to compare Tuberculosis Treatment outcomes between the two groups, and we estimated the propensity score of being a beneficiary of the BFP using a logit model. We used multinomial regression models to evaluate the effect of the BFP on Tuberculosis Treatment outcomes. Findings 1239 individuals were included in the study, of whom 196 (16%) were beneficiaries of the BFP and 1043 (84%) were not. After 6 months of Treatment, 912 (87%) of 1043 patients in the non-BFP group and 173 (88%) of 196 patients in the BFP group were cured of Tuberculosis, 103 (10%) patients in the non-BFP group and 17 (9%) patients in the BFP group had dropped out, and 25 (3%) patients in the non-BFP group and six (3%) patients in the BFP group had died. Three ( Interpretation BFP alone had a direct effect on Tuberculosis Treatment outcome and could greatly contribute to the goals of the WHO End TB Strategy. Funding Brazilian National Council for Scientific and Technological Development (CNPq) and Brazilian Ministry of Health Department of Science and Technology (DECIT).
Mauro Niskier Sanchez - One of the best experts on this subject based on the ideXlab platform.
-
effect of the bolsa familia programme on the outcome of Tuberculosis Treatment a prospective cohort study
The Lancet Global Health, 2019Co-Authors: Janaina Gomes Nascimento Oliosi, Barbara Reissantos, Rodrigo Leite Locatelli, Carolina Maia Martins Sales, Walter Gomes Da Silva Filho, Kerollen Cristina Da Silva Da Silva, Mauro Niskier Sanchez, Kaio Vinicius Freitas De Andrade, Gleide Santos De AraujoAbstract:Summary Background Social protection interventions might improve Tuberculosis outcomes and could help to control the epidemic in Brazil. The aim of this study was to evaluate the independent effect of the Bolsa Familia Programme (BFP) on Tuberculosis Treatment outcomes in Brazil. Methods We prospectively recruited and followed up individuals (aged ≥18 years) who initiated Tuberculosis Treatment at 42 health-care centres across seven cities in Brazil, between March 1, 2014, and April 30, 2017. Patients were interviewed at health-care centres and information about individual characteristics, socioeconomic status, living conditions, lifestyle, and comorbidities was recorded. Patients were separated into two groups according to BFP beneficiary status: BFP (exposed) or non-BFP (not exposed). Treatment outcome (cure, dropout, death, or development of drug-resistant Tuberculosis or Treatment failure) was recorded after 6 months of therapy. Pearson's χ2 test and ANOVA were used to compare Tuberculosis Treatment outcomes between the two groups, and we estimated the propensity score of being a beneficiary of the BFP using a logit model. We used multinomial regression models to evaluate the effect of the BFP on Tuberculosis Treatment outcomes. Findings 1239 individuals were included in the study, of whom 196 (16%) were beneficiaries of the BFP and 1043 (84%) were not. After 6 months of Treatment, 912 (87%) of 1043 patients in the non-BFP group and 173 (88%) of 196 patients in the BFP group were cured of Tuberculosis, 103 (10%) patients in the non-BFP group and 17 (9%) patients in the BFP group had dropped out, and 25 (3%) patients in the non-BFP group and six (3%) patients in the BFP group had died. Three ( Interpretation BFP alone had a direct effect on Tuberculosis Treatment outcome and could greatly contribute to the goals of the WHO End TB Strategy. Funding Brazilian National Council for Scientific and Technological Development (CNPq) and Brazilian Ministry of Health Department of Science and Technology (DECIT).
-
Effect of the Bolsa Familia Programme on the outcome of Tuberculosis Treatment: a prospective cohort study
The Lancet global health, 2019Co-Authors: Janaina Gomes Gomes Nascimento Oliosi, Mauro Niskier Sanchez, Barbara Reis-santos, Rodrigo Leite Locatelli, Carolina Maia Martins Sales Martins Sales, Walter Gomes Da Silva Filho, Kerollen Cristina Da Silva Da Silva, Kaio Vinicius Freitas De Andrade, Gleide Santos De Araújo, Priya B SheteAbstract:BACKGROUND: Social protection interventions might improve Tuberculosis outcomes and could help to control the epidemic in Brazil. The aim of this study was to evaluate the independent effect of the Bolsa Familia Programme (BFP) on Tuberculosis Treatment outcomes in Brazil. METHODS: We prospectively recruited and followed up individuals (aged ≥18 years) who initiated Tuberculosis Treatment at 42 health-care centres across seven cities in Brazil, between March 1, 2014, and April 30, 2017. Patients were interviewed at health-care centres and information about individual characteristics, socioeconomic status, living conditions, lifestyle, and comorbidities was recorded. Patients were separated into two groups according to BFP beneficiary status: BFP (exposed) or non-BFP (not exposed). Treatment outcome (cure, dropout, death, or development of drug-resistant Tuberculosis or Treatment failure) was recorded after 6 months of therapy. Pearson's χ2 test and ANOVA were used to compare Tuberculosis Treatment outcomes between the two groups, and we estimated the propensity score of being a beneficiary of the BFP using a logit model. We used multinomial regression models to evaluate the effect of the BFP on Tuberculosis Treatment outcomes. FINDINGS: 1239 individuals were included in the study, of whom 196 (16%) were beneficiaries of the BFP and 1043 (84%) were not. After 6 months of Treatment, 912 (87%) of 1043 patients in the non-BFP group and 173 (88%) of 196 patients in the BFP group were cured of Tuberculosis, 103 (10%) patients in the non-BFP group and 17 (9%) patients in the BFP group had dropped out, and 25 (3%) patients in the non-BFP group and six (3%) patients in the BFP group had died. Three (
-
Effect of the Bolsa Familia Programme on the outcome of Tuberculosis Treatment: a prospective cohort study.
The Lancet. Global health, 2018Co-Authors: Janaina Gomes Nascimento Oliosi, Rodrigo Leite Locatelli, Carolina Maia Martins Sales, Walter Gomes Da Silva Filho, Kerollen Cristina Da Silva Da Silva, Mauro Niskier Sanchez, Kaio Vinicius Freitas De Andrade, Gleide Santos De Araujo, Barbara Reis-santos, Priya B. SheteAbstract:Summary Background Social protection interventions might improve Tuberculosis outcomes and could help to control the epidemic in Brazil. The aim of this study was to evaluate the independent effect of the Bolsa Familia Programme (BFP) on Tuberculosis Treatment outcomes in Brazil. Methods We prospectively recruited and followed up individuals (aged ≥18 years) who initiated Tuberculosis Treatment at 42 health-care centres across seven cities in Brazil, between March 1, 2014, and April 30, 2017. Patients were interviewed at health-care centres and information about individual characteristics, socioeconomic status, living conditions, lifestyle, and comorbidities was recorded. Patients were separated into two groups according to BFP beneficiary status: BFP (exposed) or non-BFP (not exposed). Treatment outcome (cure, dropout, death, or development of drug-resistant Tuberculosis or Treatment failure) was recorded after 6 months of therapy. Pearson's χ2 test and ANOVA were used to compare Tuberculosis Treatment outcomes between the two groups, and we estimated the propensity score of being a beneficiary of the BFP using a logit model. We used multinomial regression models to evaluate the effect of the BFP on Tuberculosis Treatment outcomes. Findings 1239 individuals were included in the study, of whom 196 (16%) were beneficiaries of the BFP and 1043 (84%) were not. After 6 months of Treatment, 912 (87%) of 1043 patients in the non-BFP group and 173 (88%) of 196 patients in the BFP group were cured of Tuberculosis, 103 (10%) patients in the non-BFP group and 17 (9%) patients in the BFP group had dropped out, and 25 (3%) patients in the non-BFP group and six (3%) patients in the BFP group had died. Three ( Interpretation BFP alone had a direct effect on Tuberculosis Treatment outcome and could greatly contribute to the goals of the WHO End TB Strategy. Funding Brazilian National Council for Scientific and Technological Development (CNPq) and Brazilian Ministry of Health Department of Science and Technology (DECIT).
Kingsley N Ukwaja - One of the best experts on this subject based on the ideXlab platform.
-
Tuberculosis Treatment default in a large tertiary care hospital in urban nigeria prevalence trend timing and predictors
Journal of Infection and Public Health, 2012Co-Authors: Ngozi A Ifebunandu, Kingsley N UkwajaAbstract:Summary Objectives Few studies have investigated Tuberculosis Treatment default in tertiary care settings. We aimed to determine the prevalence, trend, timing and predictors of defaulting from Tuberculosis Treatment in a Nigerian tertiary hospital. Methods Data entered from 2006 to 2010 in the Federal Medical Centre, Abakaliki, Tuberculosis Treatment register were sorted into six Treatment outcomes. Five outcomes were combined into one variable called ‘non-defaulters’ and were compared with “defaulters”. The statistical analysis was conducted using SPSS. Results Of 671 Tuberculosis patients, 192 (28.6%) defaulted. Of these, 126 (66%) were ≥30 years old, and 115 (60%) had pulmonary Tuberculosis. Furthermore, 106 (55%) were males, and 125 (65%) lived in a rural area. The annual proportion of defaulters dropped from 34.8% to 20.6%, but the decreasing trend was not statistically significant ( P = 0.132 for trend). Of the defaulters, 148 (77.1%) defaulted during their intensive phase of Treatment. The median default time was 7 (IQR 5–8) weeks. The independent predictors of Treatment default were older age (aOR 1.5), rural residence (aOR 2.3), and HIV seropositivity (aOR, 2.8). Conclusion TB Treatment default is high and must be reduced. This may be achieved through improved rural DOT, further patient education, and enhanced coordination of TB/HIV care.
